Company Overview

Promethera® develops groundbreaking treatments for end-stage liver diseases

We are committed to bring patients life-saving treatments to reduce the need for liver transplantation.

We provide an end-to-end solution backed by our strong track record in the field of liver diseases, our expertise in manufacturing and the necessary supply chains to deliver these allogeneic signaling cell-based therapies to patients in need.

Our HepaStem® platform offers the first allogeneic off-the-shelf, liver derived signaling stem cell therapy for severe liver diseases that aims to bring alternative solution to liver transplantation. 

HepaStem® has a strong safety and preliminary efficacy package in both infants and children with congenital liver diseases and in adults with severe liver fibrosis and liver failure. Nearly 100 patients have been safely infused with HepaStem® worldwide. 

Promethera®’s HepaStem® advanced cell therapy platform for severe liver disease

Promethera®'s  headquarters are in Belgium’s Walloon region, which is an internationally reknown hub for biotechnology and cell therapy research. The addition of our Durham, NC, US liver sourcing and manufacturing capabilities, and our strong investor’s consortium presence in Asia position Promethera® as a worldwide pioneer company in cirrhotic liver diseases.

Promethera® is committed to further strengthening its research and development capabilities, through both internal development activities, partnerships and potentially through strategic transactions.